The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer

BACKGROUND: UGT1A1 polymorphisms should be considered when using irinotecan-containing regimens, especially in patients with a double-variant-type (DV), including homozygous for UGT1A1*28 and UGT1A1*6 and heterozygous for both UGT1A1*28 and UGT1A1*6. We investigated the safety and efficacy of modifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Satake, Tomoyuki, Morizane, Chigusa, Maruki, Yuta, Ohba, Akihiro, Nagashio, Yoshikuni, Kondo, Shunsuke, Hijioka, Susumu, Ueno, Hideki, Okusaka, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309143/
https://www.ncbi.nlm.nih.gov/pubmed/35637361
http://dx.doi.org/10.1007/s10147-022-02186-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309143/
https://www.ncbi.nlm.nih.gov/pubmed/35637361
http://dx.doi.org/10.1007/s10147-022-02186-w

Ejemplares similares